A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Dec 2018
At a glance
- Drugs Masitinib (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors AB Science
- 07 Dec 2018 Planned number of patients changed from 406 to 495.
- 19 Oct 2017 Results presented in a AB Science Media Release.
- 27 Apr 2017 New trial record